Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Condition(s) studied
Investigational drug(s) / intervention(s)
Blood sample taken for the liquid biopsy: 36 mL will be taken for the study.
Study summary
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Eligibility
Primary outcome measure(s)
- Sensitivity of liquid biopsy versus solid biopsy (gold standard) — 1 month
The primary endpoind is the sensitivity of liquid biopsy versus solid biopsy as the gold standard for detecting genomic alterations evaluated in the studied gene panel. The panel will consist of 70 genes common to the PanoraMix panels (125 genes, FFPE) and Avida (104 genes, cpDNA).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Antoine Lacassagne | Nice | France | Recruiting |
More Centre Antoine Lacassagne trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06606366 on ClinicalTrials.gov ↗ ← All trials in France